Metabolic Barriers to T Cell Function in Tumors
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
The metabolic programs that drive T cell functions are exquisitely sensitive to cell intrinsic and extrinsic factors, allowing T cells to respond in a fine-tuned manner to a variety of immune challenges and conditions. However, many of the factors essential for effector T cell function are perturbed in the tumor microenvironment, where oncogenic mutations drive unrestrained cancer cell growth that leads to excess nutrient consumption, excess waste excretion, and insufficient oxygen delivery. This imposes metabolic constraints on infiltrating cells that result in dysfunction and loss of potential antitumor activity in both naturally occurring as well as tailored T cells introduced as part of immunotherapy. In this review, we highlight the metabolic properties that characterize tumor-infiltrating T cells, the barriers within the metabolic landscape of the tumor microenvironment, and the opportunities and challenges they present in development of new cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is known that mesothelioma cells increase the expression of L-type Amino acid Transporter 1 (LAT1), depriving T-cells of amino acids, such as arginine and tryptophan, which are essential for T-cell function and proliferation [121].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mesothelioma cells could also inhibit T-cell glycolysis and functions, increasing the levels of indoleamine-pyrrole 2,3-dioxygenase (IDO), which degrades tryptophan into kynurenine, a well-known immunosuppression factor [121,123,124].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the mesothelioma microenvironment, the availability of glucose is critical, and competition for this molecule impacts on T-cell function and the recruitment of immune infiltrating cells, promoting angiogenesis [119,120,121,122].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [121]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 2×
“required for maintaining the TCA cycle as well as a vital source for lipid synthesis through reductive carboxylation in hypoxic cancer cells (1) and Teff cells (2).”
BackgroundCommensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549 · cited 1×
“Both in vitro and in vivo studies in the gut suggest short chain FAs can induce Treg cell differentiation (67, 68), although this may be through changes in G protein–coupled receptor-mediated signaling rather than direct use as a metabolic fuel.”
BackgroundThe Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413 · cited 1×
“Both in vitro and in vivo studies in the gut suggest short chain FAs can induce Treg cell differentiation (67, 68), although this may be through changes in G protein–coupled receptor-mediated signaling rather than direct use as a metabolic fuel.”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 1×
“Consider PD-1 blockade, which has yielded promising results in many cancer patients, but not so in a sizeable population of patients (83).”
BackgroundKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · cited 1×
“Increased HIF1a activity promotes aerobic glycolysis and reduces OXPHOS by upregulating pyruvate dehydrogenase kinase (PDK1) and lactate dehydrogenase A (26, 27), effectively shunting pyruvate away”
BackgroundMetabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172 · cited 1×
“Hypoxia and upregulation of HIF1a in tumors are both associated with poor clinical outcomes in cancer patients (69).”
BackgroundFunctional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046 · cited 1×
“Additionally, lactate has been shown to stabilize HIF1a in macrophages (74), and can be predicted to have similar effects in T cells.”
BackgroundIschaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907
Understanding the Intersections between Metabolism and Cancer Biology
Vander Heiden, M. G., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,293
Research works printed but not linked: 3
- Michalek RD Gerriets VA Jacobs SR Macintyre AN MacIver NJ Mason EF Sullivan SA Nichols AG Rathmell JC 2011 Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets The Journal of Immunology 186 3299 3303 21317389 PMC3198034
- Gerriets VA Kishton RJ Johnson MO Cohen S Siska PJ Nichols AG Warmoes MO de Cubas AA MacIver NJ Locasale JW Turka LA Wells AD Rathmell JC 2016 Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression Nat Immunol 17 1459 1466 27695003 PMC5215903
- Frauwirth KA Riley JL Harris MH Parry RV Rathmell JC Plas DR Elstrom RL June CH Thompson CB 2002 The CD28 Signaling Pathway Regulates Glucose Metabolism Immunity 16 769 777 12121659
Cited by
Items 201–223 of 223
Additional file 1 of Lipid metabolic features of T cells in the Tumor Microenvironment
Lou, W., Chaoju, 宫. G., Ye, Z., Hu, Y., Zhu, M., Fang, Z., & Xu, H. (2022) · Figshare · doi:10.6084/m9.figshare.21291857
López Cabrera, E. (2024) · UCL Discovery (University College London)
IL RUOLO DELL’IMMUNITA INNATA NEL COVID-19 GRAVE
Cossarizza, A., Vinceti, M., & Borella, R. (2023) · IRIS UNIMORE (University of Modena and Reggio Emilia)
PIM Kinase Alters the Prostate Tumor Immune Microenvironment
Clements, A. N., & Clements, A. N. (2024) · UA Campus Repository (The University of Arizona) · Cited by 1
Leung, Y. S. L. (2021) · TSpace (University of Toronto)
Impact de la radiothérapie interne vectorisée alpha sur le microenvironnement tumoral
Perrin, J. (2021) · theses.fr (ABES) · doi:10.70675/31c91866z101fz4e07zbde2z6887a8fdba6d
Zhou, X., Chen, S., & Liang, J. (2026) · Discover Oncology · doi:10.1007/s12672-026-05523-x
“In many cases, the limiting problem is that effector cells either fail to reach the relevant tumour compartments or rapidly lose function after entry [4, 132].”
PCIF1 loss licenses antitumour immunity via cholesterol biosynthesisPreprint
Li, K., Lu, T., Ding, Z., Wang, M., Roy, S., Deng, Y., Benannoune, N., Wang, Y., Edmond, E., Scoazec, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.11.737975
Zhang, Z., Liang, X., Tian, Y., Li, C., Cao, X., Wang, D., Xie, A., Liu, S. X., Lin, K., Li, Q., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015617
Targeting metabolic reprogramming in cancer: Past, present, and future
Kumari, N., Shukla, S. K., & Thakur, R. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109109
CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation
Xu, P. J., Zhang, Z. J., Jin, J., Xu, H. Y., Gu, Y. X., Yang, Q. Q., & Zhou, Y. L. (2026) · Advanced Science · doi:10.1002/advs.77503
“However, supporting evidence is derived mainly from oncology models, and their effectiveness in chronic fibrotic tissues remains to be established [ 122, 123 ].”
Ghais, A., Rizkallah, J., Wehbeh, B. E. D., Diab, Y., Awada, A., Atwi, M., Ayoub, R., Mina, C., Rammal, F., badr, A., et al. (2026) · Cancers · doi:10.3390/cancers18172829
“The tumor’s unusual vasculature creates an oxygen gradient with a hypoxic core [75], confining T cells to perivascular regions while immunosuppressive cells populate the core.”
Huang, Y., Zhang, J., Lou, J., Bian, B., Zhang, M., Gou, T., Jiang, T., & Zhang, G. (2026) · Cells · doi:10.3390/cells15181676
Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death
Levchuk, K., Petukhov, A., Tursymbek, S., Seitkamal, K., Bertleuova, A., Bulanin, D., & Barlev, N. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1963794
“Finally, unfavorable physicochemical conditions, including hypoxia, acidosis, and lactate accumulation, impose metabolic stress on T-cells and promote their early dysfunction (9 – 11).”
Nanomaterials Reshaping Tumor Metabolism: A New Frontier to Overcome T Cell Exhaustion
Zhu, X., He, L., Li, J., Guo, S., Liu, X., Cao, Y., & Song, S. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s639887
Advanced Nanomedicines for Cancer Metabolic Therapy
Duan, Q., Tian, C., Cheng, X., Wang, L., Huo, M., & Shi, J. (2026) · Advanced Materials · doi:10.1002/adma.75365
Benejova, K., Travis, K., Mathur, D., Song, N., Li, Z., Phelps, M. A., Mardis, E. R., Makowski, L., Carbone, D. P., Owen, D. H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.24.761570
Wang, Z., Feng, D., Zhang, S., Xu, S., Shen, X., Lee, R. J., Tang, Y., Xie, J., Wu, X., & He, X. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.183583
RNA m6A Modification in Immunometabolism: Context-Dependent Mechanisms and Therapeutic Perspectives
Fang, Q., Li, W., Cai, Y., Zhang, S., Tang, X., Chu, C., Zhou, M., Li, F., Zhang, Z., & Li, X. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219566
Wen, Y. Y., & Li, L. Z. (2026) · Journal of Biomedical Optics · doi:10.1117/1.jbo.31.11.115002
Yang, W., Denger, A., Diener, C., Küppers, F., Soriano-Baguet, L., Schäfer, G., Yanamandra, A. K., Zhao, R., Knörck, A., Schwarz, E. C., et al. (2022) · doi:10.3389/fimmu.2022.831680.s002
Zhang, Z., Mao, M., Wang, F., Zhang, Y., Shi, J., Chang, L., Wu, X., Zhang, Z., Xu, P., & Lu, S. (2023) · doi:10.3389/fimmu.2023.1164669.s011
Metadata
- Authors
- Sugiura, A., & Rathmell, J. C.
- Affiliations
- Vanderbilt-Ingram Cancer Center (US)
- Corresponding author
- Rathmell, Jeffrey C
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 200
- Issue
- 2
- Pages
- 400-407
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC5777533
- OpenAlex
- W2784164696
- Cited by
- 208
- References
- 89
- Citations by year
- 2026: 22 · 2025: 18 · 2024: 15 · 2023: 30 · 2022: 35 · 2021: 32 · 2020: 29 · 2019: 18 · 2018: 9
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (T32GM007347)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK105550)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- T cell metabolism, tumor microenvironment, tumor-infiltrating T cells, T cell dysfunction, cancer immunotherapy, nutrient consumption, oxygen delivery, oncogenic mutations, cancer therapeutics
- MeSH terms
- Animals, Energy Metabolism, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.